Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New targeted therapies for malignant lymphoma based on molecular heterogeneity.

Expert review of hematology - 1 Jan 2017

Horn Heike, Staiger Annette M, Ott German

Abstract excerpt

INTRODUCTION: Owing to tremendous advances in the understanding of mechanisms involved in the pathogenesis of malignant tumors an emerging field of novel targeted drugs has evolved within the last decade. This is of particular interest also for malignant lymphomas, constituting a heterogeneous tumor category with substantial variation in clinical outcome, ranging from indolent forms that do not require treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Combined Modality Therapy
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Heterogeneity

Share to Immunotherapy

Share to Lymphoma

Share to Molecular Targeted Therapy

Share to Tumor Microenvironment

Source

Identifiers

PMID: 27918211
DOI: 10.1080/17474086.2017.1268046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New targeted therapies for malignant lymphoma based on molecular heterogeneity.PMID 27918211Read ↗

Malignant lymphoma: pathophysiology and current therapy.Semantic proximity Read ↗

Novel Therapeutics for Aggressive Non-Hodgkin's LymphomaSemantic proximity Read ↗

Precision therapy for lymphoma--current state and future directions.Semantic proximity Read ↗

Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Semantic proximity Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

New Insights into Lymphoma PathogenesisSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Unraveling MCL biology to understand resistance and identify vulnerabilitiesSemantic proximity Read ↗

Development of molecular intervention strategies for B-cell lymphoma.Semantic proximity Read ↗

Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance.Semantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Immune Checkpoint Inhibitors to Treat Malignant LymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.